Objective
Atherosclerosis is a chronic disease characterized by the accumulation of lipids in the arteries accompanied by a local inflammatory response. The nuclear receptor peroxisome proliferator-activated receptor alpha (PPARa) appears to affect the development o f atherosclerotic lesions through its metabolic and anti-inflammatory effects. The role of PPARa in the control of lipid and lipoprotein metabolism has been extensively studied. Moreover, the role of murine PPARa has been studied in vivo using different mo use models of atherosclerosis. However, little is known on the activity of human PPARa in vivo in the vascular system. Therefore, the Goal of this project is to characterize the role of human PPARa protein in the control of vascular inflammation using an original humanized PPARa animal model (KIPPARa mice).
To analyze the role of human PPARa protein in the atherogenic process in vivo, we will cross the KI-PPARa mice with an atherosclerotic mice model, such as the KIapoE2 mice. These mice exhibit plasma lipo protein characteristics that are equivalent to those of type III and IIB hyperlipidemic subjects, they develop spontaneous atherosclerotic lesions and they also respond to atherogenic high fat and cholesterol diets. KIPPARa mice have been recently generated in the host laboratory.
This model has been validated by checking human PPARa mRNA and protein expression in different tissues. The metabolic consequences of human PPARa expression in KIPPARa mice are currently being analysed in the host laboratory. Therefore, taking into account both models, the generation of KIPPARa; KIapoE2 mouse model will be our original main tool to carry out this project. The results are anticipated to open new perspectives for human PPARa as a molecular target for the treatment of atherosclerosis.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences biological sciences biochemistry biomolecules lipids
- medical and health sciences health sciences nutrition
- medical and health sciences basic medicine physiology
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-MOBILITY-5
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LILLE
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.